Compare Salesforce Inc (CRM) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Crispr Therapeutics AG — how do they compare? Salesforce Inc trades at $170.01 (market cap $137.23B), while Crispr Therapeutics AG trades at $50.63 (market cap $4.97B). The key difference: Salesforce Inc is far larger — about 27.6× Crispr Therapeutics AG's market cap, and Salesforce Inc pays a 1.05% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRM | CRSP | |
|---|---|---|
Market Cap | $137.23B | $4.97B |
Sector | Technology | Health |
52-Week High | $270.25 | $76.78 |
52-Week Low | $150.12 | $44.34 |
Enterprise Value | $167.28B | $3.32B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $171.28, showing minimal daily movement (+0.04%) amid recent market volatility. The stock demonstrates strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while the stock trades near key support at $170. Recent news highlights AI momentum and market concerns about software sector performance.
CRM presents a compelling investment case with strong analyst support (76.84% buy rating) and significant upside to the $235.90 consensus target. However, investors face risks from sector-wide software selloffs, competitive AI landscape pressures, and the stock's 35% YTD decline requiring careful evaluation of growth sustainability versus current valuation discounts.
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
